Volume | 489,594 |
|
|||||
News | (1) | ||||||
Day High | 1.38 | Low High |
|||||
Day Low | 1.33 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.35 | 1.33 | 1.38 | 1.37 | 1.34 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,670 | 489,594 | US$ 1.35 | US$ 661,037 | - | 1.025 - 2.85 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:46 | formt | 100 | US$ 1.37 | USD |
ATAI Life Sciences NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
225.77M | 166.01M | - | 314k | -40.22M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ATAI Life Sciences NV News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.47 | 1.485 | 1.31 | 1.35 | 811,203 | -0.10 | -6.80% |
1 Month | 1.87 | 1.89 | 1.30 | 1.55 | 1,027,544 | -0.50 | -26.74% |
3 Months | 1.65 | 2.85 | 1.30 | 2.04 | 1,468,890 | -0.28 | -16.97% |
6 Months | 1.21 | 2.85 | 1.18 | 1.92 | 1,479,245 | 0.16 | 13.22% |
1 Year | 1.80 | 2.85 | 1.025 | 1.80 | 1,136,685 | -0.43 | -23.89% |
3 Years | 21.00 | 22.91 | 1.025 | 3.85 | 976,537 | -19.63 | -93.48% |
5 Years | 2.13 | 22.91 | 1.025 | 3.83 | 890,670 | -0.76 | -35.68% |
ATAI Life Sciences NV Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |